Inactive Instrument

Analyst Reco. Biodel Inc Nasdaq

Equities

US09064M2044

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

Guggenheim Downgrades Albireo Pharma to Neutral From Buy	11/01/23	MT
Cowen Downgrades Albireo Pharma to Market Perform From Outperform, Adjusts Price Target to $48 From $68	11/01/23	MT
Jefferies Downgrades Albireo Pharma to Hold From Buy, Adjusts Price Target to $42 From $49	11/01/23	MT
Baird Adjusts Price Target on Albireo Pharma to $45 From $55, Maintains Outperform Rating	10/01/23	MT
HC Wainwright Downgrades Albireo Pharma to Neutral From Buy, Price Target is $42	10/01/23	MT
Wedbush Downgrades Albireo Pharma to Neutral From Outperform After News of Sale to Ipsen, Lowers Price Target to $42 From $53	09/01/23	MT
Wedbush Trims Albireo Pharma's Price Target to $53 From $54 on Increased Share Count, Keeps Outperform Rating	09/11/22	MT
HC Wainwright Adjusts Albireo Pharma Price Target to $68 From $54, Maintains Buy Rating	12/10/22	MT
Baird Raises Albireo Pharma's Price Target to $55 From $43, Maintains Outperform Rating	12/10/22	MT
Wedbush Adjusts Albireo Pharma Price Target to $54 From $52, Maintains Outperform Rating	11/10/22	MT
Baird Adjusts Albireo Pharma's Price Target to $43 from $40, Maintains Outperform Rating	23/09/22	MT
Wedbush Adjusts Albireo Pharma Price Target to $52 From $61, Maintains Outperform Rating	22/09/22	MT
Guggenheim Initiates Albireo Pharma at Buy Rating With $55 Price Target	08/09/22	MT
Wedbush Removes Outperform-Rated Albireo Pharma From Best Ideas List; Price Target is $61	17/08/22	MT
Wedbush Cuts Price Target on Albireo Pharma to $61 From $72 on Bylvay Sales Estimates; Outperform Rating Kept	16/08/22	MT
Baird Adjusts Albireo Pharma's Price Target to $40 From $66, Keeps Outperform Rating	16/08/22	MT
HC Wainwright Adjusts Albireo Pharma's Price Target to $54 From $80, Keeps Buy Rating	16/08/22	MT
Wedbush Cuts Price Target on Albireo Pharma to $61 From $72 on Bylvay Sales Estimates; Outperform Rating Kept	16/08/22	MT
Baird Adjusts Price Target for Albireo Pharma to $66 From $72, Maintains Outperform Rating	17/05/22	MT
Wedbush Trims Albireo Pharma's Price Target to $72 From $75, Citing Bylvay Penetration Estimates; Outperform Rating Kept	17/05/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Biodel Inc Nasdaq

Equities

US09064M2044

Analyst Reco.

Filters